Compare Norfolk Southern Corporation (NSC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs ResMed Inc. — how do they compare? Norfolk Southern Corporation trades at $317.79 (market cap $71.20B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Norfolk Southern Corporation is far larger — about 2.2× ResMed Inc.'s market cap, and Norfolk Southern Corporation pays the higher dividend (1.7%). Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and ResMed Inc. for 51 Days on average.
| NSC | RMD | |
|---|---|---|
Market Cap | $71.20B | $31.89B |
Volume | 555,248 | 618,314 |
Sector | Industrials | Health |
52-Week High | $352.98 | $275.96 |
52-Week Low | $278.19 | $182.82 |
Typical Hold Time | 33 Days | 51 Days |
Enterprise Value | $86.75B | $31.24B |
Dividend Yield | 1.7% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $316.99, up 1.21% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, a 21.02% net income margin, and a 16.97% ROE. Recent news highlights progress on the Union Pacific merger, expected to close by late 2027, and a dividend of $1.35 payable in August 2026. Cash flow remains positive from operations despite net outflows.
NSC presents a favorable investment case with analyst consensus at Buy and a $361.86 price target, implying 14% upside. Key risks include merger regulatory hurdles and fuel cost pressures. The combination with Union Pacific offers long-term growth potential, but investors should monitor STB approval timelines and operating ratio trends.
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
